Alice Mims

Ohio State University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

James Blachly

Associate Professor of Internal Medicine

Ohio State University

UNITED STATES

View details

Shelley Orwick

Ohio State University

UNITED STATES

View details

Michael Savona

Beverly and George Rawlings Director of Hematology Research and Professor of Medicine and Cancer Biology

Vanderbilt University

UNITED STATES

View details

Dimitrios Papaioannou

Assistant Professor

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

UNITED STATES

View details

Mark J. Levis

Johns Hopkins University

UNITED STATES

View details

Yazan F. Madanat

UNITED STATES

View details

Annette Kim

Associate Professor

Brigham and Women's Hospital and Harvard Medical School

UNITED STATES

View details

Deedra Nicolet

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alice Mims

Research Interests

Explore related searches

Contact this professor

Articles (12)

Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML

MRD in AML: who, what, when, where, and how?

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

A precision medicine classification for treatment of acute myeloid leukemia in older patients

Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations

Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS

Collaborators (8)

James Blachly

Shelley Orwick

Michael Savona

Dimitrios Papaioannou

Mark J. Levis

Yazan F. Madanat

Annette Kim

Deedra Nicolet

Make your next move.